NGS

Global and Regional MRD Testing Market Analysis Report 2024: Revolutionizing Cancer Patient Management, Rising Consumer Awareness Spurs Demand for MRD Testing - Forecast to 2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Surgery, Medical Devices, Hospitals, Genetics, Health Technology, Biotechnology, Radiology, Health, Oncology, Hospital, PCR, Flow cytometry, Chronic leukemia, Growth, Bone marrow, Incidence, Integration, Patient, NGS, IDT, Research, Health care, Multiple myeloma, Acquisition, Cancer, Medicare, Medicine, Karyotype, MRD, Haematopoietic system, Region, GRAIL, Throttle position sensor, Lymphoma, Polymerase chain reaction, Medical imaging

The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The MRD testing market is driven by several factors, including the expansion in medicare coverage for MRD testing and the administration of solid tumor diagnosis.
  • In recent years, as consumer awareness has grown, there has been an increasing demand for MRD testing.
  • The global MRD testing market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients.

NGS Is First to Market with Revolutionary 3M Glazing Security Product – S2400

Retrieved on: 
Wednesday, March 27, 2024
Commercial Building & Real Estate, Technology, Construction & Property, Interior Design, Building Systems, Other Energy, Security, Other Technology, Energy, Hardware, Other Construction & Property, Multimedia, NGS, Interest, Safety

NGS worked directly with 3M to field-test and provide feedback to help bring this product to market.

Key Points: 
  • NGS worked directly with 3M to field-test and provide feedback to help bring this product to market.
  • View the full release here: https://www.businesswire.com/news/home/20240327037471/en/
    “We’re so excited to be the first dealer-installer to bring 3M S2400 to market,” states James Beale, CEO.
  • “This innovative product is a game-changer for glazing security and building perimeter security.
  • NGS is excited to bring 3M S2400 to clients who value the safety and security of their buildings.

BostonGene Recognized as Designated Laboratory for the ComboMATCH Precision Medicine Clinical Trial

Retrieved on: 
Tuesday, March 26, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Oncology, NCI, Combination, Gene, ECOG, Physician, Patient, Malignancy, NGS, Biomarker, Research, DNA, RNA, Tumor microenvironment, National Cancer Institute, WES, Cancer, MD, Medicine, Microsatellite instability, Clinical trial, RNA-Seq, Bangladesh Technical Education Board, Drug resistance

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.
  • ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial.
  • Already a CAP-accredited and CLIA-certified lab, BostonGene will now serve as a designated NGS laboratory for ComboMATCH.
  • “Our participation in the ComboMATCH trials underscores our commitment to advancing precision cancer medicine,” says Nathan Fowler, MD, Chief Medical Officer at BostonGene.

MiLaboratories Introduces Platforma Bio: A Revolutionary UI-First Computational Biology Platform powered by AI

Retrieved on: 
Monday, March 25, 2024
Technology, Research, Stem Cells, Software, Biotechnology, Health, Other Science, Science, Artificial Intelligence, Computational biology, Multimedia, NGS, Organization, Interest, UI, AI, Data analysis, Online shopping

MiLaboratories, a leader in developing best-in-class software for immunological data analysis, proudly announces the official launch of Platforma.bio .

Key Points: 
  • MiLaboratories, a leader in developing best-in-class software for immunological data analysis, proudly announces the official launch of Platforma.bio .
  • This groundbreaking computational biology platform, powered by AI large language models, is designed to significantly streamline, and simplify biological analysis, making it more accessible to researchers across various disciplines.
  • Platforma.bio stands out in the computational biology field with its unique, patent-pending engine that effectively identifies and eliminates redundant computations.
  • To introduce Platforma.bio to the research community, MiLaboratories will host a detailed webinar showcasing its features and practical applications.

Elegen Launches ENFINIA™ DNA Enhancement for Rapid Synthesis of Highly Complex DNA

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, SV40, Associate, GSK, NGS, RNA, DNA, EAP, Messenger, Cauliflower mosaic virus, Doctor of Philosophy, Lentivirus, Therapy, IRES, Access, Orbital, IVT, Vaccine

This upgrade to ENFINIA DNA sets a new standard for DNA manufacturing, providing an industry-leading combination of speed, length, NGS-verified accuracy and complexity.

Key Points: 
  • This upgrade to ENFINIA DNA sets a new standard for DNA manufacturing, providing an industry-leading combination of speed, length, NGS-verified accuracy and complexity.
  • EAP partners received long and very complex DNA sequences that were either rejected by other suppliers or would have taken months to synthesize.
  • Elegen commercially launched ENFINIA DNA in Q1 2023 , delivering NGS-verified, linear DNA up to 7kb in 6 to 8 business days.
  • This latest enhancement of ENFINIA DNA to produce high-complexity DNA marks another step in the company’s mission to develop innovative solutions for DNA manufacturing, including even longer DNA, plasmid DNA and clinical-grade DNA production.

Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Research, Pharmaceutical, Oncology, Health, Genetics, Other Health, CE, Thermo Fisher Scientific, CDX, Patient, NGS, Bayer, Executive Committee, Neoplasm, Liquid biopsy, Pharmaceutical industry

Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.

Key Points: 
  • Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.
  • These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.
  • Pairing this with Bayer’s growing precision oncology portfolio, we are well-positioned for the potential to help ensure that eligible patients can be quickly matched with the right treatment.”
    Financial terms of the cooperation were not disclosed.
  • *The Genexus Dx instrument and the Oncomine Dx Express Test are currently CE-IVD and are only available in countries that accept the CE mark.

Eaton delivers FAA-approved Boeing 737 Next Generation / 737 MAX oxygen sensor replacement to commercial aviation aftermarket

Retrieved on: 
Tuesday, March 19, 2024
Other Manufacturing, Air, Engineering, Transport, Aerospace, Manufacturing, Machinery, Other Travel, Transportation, Travel, ASM, Environment, NGS, Boeing, Quality of life, OEM, Safety, MAX, Federal Aviation Administration, Airline

Eaton’s oxygen sensor is a form, fit and functional replacement for the OEM Boeing 737 NG / 737 MAX sensor.

Key Points: 
  • Eaton’s oxygen sensor is a form, fit and functional replacement for the OEM Boeing 737 NG / 737 MAX sensor.
  • In response to the market need for a more reliable oxygen sensor, Eaton’s replacement is designed from its proven high-performance commercial and military oxygen sensor that provides cost savings through increased reliability and time on wing.
  • The replacement Boeing 737 NG / 737 MAX oxygen sensor (part number 3270108-0101) complements Eaton’s existing highly reliable Boeing 737 NG / 737 MAX air separation module replacement for the same platform.
  • To learn more about Eaton’s NGS oxygen sensor and ASM, visit NGS oxygen sensor | Aerospace | Eaton .

Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines

Retrieved on: 
Wednesday, March 20, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, CE, Thermo Fisher Scientific, CDX, Patient, NGS, Bayer, Executive Committee, Neoplasm, Liquid biopsy, Pharmaceutical industry

Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.

Key Points: 
  • Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.
  • These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.
  • Pairing this with Bayer’s growing precision oncology portfolio, we are well-positioned for the potential to help ensure that eligible patients can be quickly matched with the right treatment.”
    Financial terms of the cooperation were not disclosed.
  • *The Genexus Dx instrument and the Oncomine Dx Express Test are currently CE-IVD and are only available in countries that accept the CE mark.

Genseq Selects Sapio LIMS to Power Best-in-Class Next-Generation Sequencing Services

Retrieved on: 
Monday, March 18, 2024
Software, Research, Professional Services, Pharmaceutical, Data Management, Apps, Applications, Technology, Health Technology, Data Analytics, Science, Biotechnology, Health, Other Science, Quality control, Genomics, Laboratory information management system, Communication, LIMS, NGS, AI, CAP, ELN, Al Ain Oasis, GxP, Fine chemical

Founded in 2023, Genseq uses state-of-the-art sequencing platforms, including Novaseq, Nextseq, and Nextseq Dx, to ensure excellent quality and accuracy in sequencing data generation.

Key Points: 
  • Founded in 2023, Genseq uses state-of-the-art sequencing platforms, including Novaseq, Nextseq, and Nextseq Dx, to ensure excellent quality and accuracy in sequencing data generation.
  • In addition to providing a full range of genomics, transcriptomics, and single-cell sequencing services, Genseq’s biobanking facility can accommodate more than 500,000 samples.
  • Genseq will use the advanced LIMS functionality from Sapio to track all aspects of sample management , including sample accessioning, storage, quality control, and aliquoting.
  • “Sapio is supporting Genseq in meeting its promise to clients, and we’re excited to partner with them as they grow their capabilities to meet demand.”

seqWell Launches First Assay-ready, 384-well Library Preparation Kit to Enable Ultra-high Throughput Plasmid and Synthetic Construct Sequencing

Retrieved on: 
Monday, March 18, 2024
Science, Biotechnology, Research, Medical Supplies, General Health, Health, Health Technology, Genetics, Entrepreneurship, Synthetic biology, NGS, Workflow, Plastic, Multimedia, Plasmid, DBTL

ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower cost, high throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology.

Key Points: 
  • ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower cost, high throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology.
  • View the full release here: https://www.businesswire.com/news/home/20240318055628/en/
    seqWell's ExpressPlex HT 384-well library prep kit is the first commercially available next-generation sequencing library preparation kit enabling multiplexing up to 6,144 samples in a pre-plated 384-well format.
  • (Graphic: Business Wire)
    “ExpressPlex HT was a natural step in broadening our portfolio of scalable, multiplex library preparation solutions,” said Jack Leonard, Chief Technology Officer at seqWell.
  • Massive multiplexing using 6,144 indices and a fully automated, 90-minute library preparation workflow enable 24-hour sample-to-answer turnaround for greater than 6,000 samples.